T1	p 178 197	diabetic patients :
T2	p 676 741	, 360 diabetic patients with coronary artery disease were treated
T3	p 2458 2466	patients
T4	p 2559 2607	diabetic patients with coronary artery disease .
T5	i 45 56	lipoprotein
T6	i 119 131	pioglitazone
T7	i 216 240	PERISCOPE ( Pioglitazone
T8	i 451 463	pioglitazone
T9	i 582 594	Pioglitazone
T10	i 628 639	glimepiride
T11	i 747 774	pioglitazone or glimepiride
T12	i 796 820	PERISCOPE ( Pioglitazone
T13	i 1568 1580	pioglitazone
T14	i 1758 1769	glimepiride
T15	i 2356 2368	pioglitazone
T16	o 45 68	lipoprotein cholesterol
T17	o 467 487	atheroma progression
T18	o 559 579	atheroma progression
T19	o 602 613	progression
T20	o 934 954	atheroma progression
T21	o 1042 1118	biochemical parameters , percent atheroma volume , and total atheroma volume
T22	o 1197 1349	increases in high-density lipoprotein cholesterol ( HDL-C ) and reductions in glycated hemoglobin , triglycerides , and C-reactive protein . Significant
T23	o 1396 1439	percent atheroma volume and triglycerides (
T24	o 1464 1488	triglyceride/HDL-C ratio
T25	o 1515 1540	and glycated hemoglobin (
T26	o 1598 1635	low-density lipoprotein cholesterol (
T27	o 1709 1727	apolipoprotein A-I
T28	o 1772 1805	Substantial atheroma regression ,
T29	o 1818 1829	progression
T30	o 1860 1887	relative increases in HDL-C
T31	o 1941 1957	in triglycerides
T32	o 1995 2019	triglyceride/HDL-C ratio
T33	o 2067 2091	in glycated hemoglobin (
T34	o 2245 2270	percent atheroma volume (
T35	o 2286 2309	total atheroma volume (
T36	o 2425 2445	atheroma progression